Author:
Fuller Heidi,Barišić Marija,Šešo-Šimić Đurđica,Špeljko Tea,Morris Glenn,Šimić Goran
Abstract
AbstractProgress in understanding the genetic basis and pathophysiology of spinal muscular atrophy (SMA), along with continuous efforts in finding a way to increase survival motor neuron (SMN) protein levels have resulted in several strategies that have been proposed as potential directions for efficient drug development. Here we provide an overview on the current status of the following approaches: 1) activation of SMN2 gene and increasing full length SMN2 transcript level, 2) modulating SMN2 splicing, 3) stabilizing SMN mRNA and SMN protein, 4) development of neurotrophic, neuroprotective and anabolic compounds and 5) stem cell and gene therapy. The new preclinical advances warrant a cautious optimism for emergence of an effective treatment in the very near future.
Reference159 articles.
1. Botta A., Tacconelli A., Bagni I., Giardina E., Bonifazi E., Pietropolli A., et al., Transmission ratio distortion in the spinal muscular atrophy locus: data from 314 prenatal tests, Neurology, 2005, 65, 1631–1635
2. Bromberg M. B., Swoboda K. J., Motor unit number estimation in infants and children with spinal muscular atrophy, Muscle Nerve, 2002, 25, 445–447
3. Crawford T. O., Pardo C. A., The neurobiology of childhood spinal muscular atrophy, Neurobiol Dis, 1996, 3, 97–110
4. Dubowitz, Disorders of the lower motor neuron, the spinal muscular atrophy, 1995, in: Dubowitz (ed), Muscle disorders in childhood, Saunders, London, 325–369
5. Greenfield J.C., Stern R.O., The anatomical identity of the Werdnig-Hoffmann and Oppenheim forms of infantile muscular atrophy, Brain, 1927, 50, 652–686
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献